Market Overview:
The global estrogen receptor beta market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of estrogen receptor-positive cancers, rising awareness about women’s health issues, and growing demand for targeted therapies. Based on type, the global estrogen receptor beta market is segmented into erteberel, estetrol, fosfestrol, fulvestrant, and others. The erteberel segment is expected to account for the largest share of the market in 2018 owing to its high efficacy and safety profile. Based on application, the global estrogen receptor beta market is segmented into women’s health, metabolic disorder, dermatology,, immunology,, and others. The women’s health segment accounted for the largest share of the market in 2017 due to rising incidence rates of breast cancer across all regions worldwide.
Product Definition:
The estrogen receptor beta (ERβ) is a protein that in humans is encoded by the ESR2 gene. ERβ is one of two types of estrogen receptors, the other being ERα. The main function of estrogen receptors is to regulate gene transcription.
Erteberel:
Erteberel (Para-Amino Benzoic Acid) is an organic compound, which is soluble in water and slightly soluble in alcohol. It has a slight odor of vanilla. It was first discovered and patented by the German Chemist Dr. Gerhard Ertebereg in 1808, who named it after himself as Ertheiol or Etherol.
Estetrol:
Estetrol is a naturally occurring chemical in the plant kingdom. It is extracted from plants and used to make perfume, soaps, cosmetics, and other products. Estetrol has estrogen-like effects but unlike estradiol it does not have any adverse effects on the uterus or breasts.
Application Insights:
The women¢â‚¬â„¢s health segment dominated the global estrogen receptor beta market in terms of revenue share in 2017. This is due to the rising prevalence of various female reproductive disorders such as polycystic ovary syndrome (PCOS), uterine cancer, and breast cancer. According to WHO, around 1 in 8 women are estimated to develop some form of cancer during their lifetime. Moreover, according to Breastcancer.org., around 1-in-8 U.
Regional Analysis:
North America dominated the global ER beta market in 2017. The presence of a large number of pharmaceutical companies and favorable reimbursement policies are some factors contributing to its largest share. In addition, increasing awareness about women's health issues is also expected to drive growth during the forecast period. Asia Pacific is expected to be the fastest-growing region over the next eight years owing to rising healthcare expenditure levels, growing population base, and improving economic conditions in emerging countries such as China & India & Indonesia etcetera.
In addition, an increase in disease prevalence rates due to changing lifestyles has also contributed significantly towards regional growth over recent years; for instance diabetes type 2 (non-insulin dependent) which was rare 10 years ago has been reported at 1% among Asian population whereas it increased up t o 3% among Asian population recently (2010).
Growth Factors:
- Increasing prevalence of estrogen receptor beta-positive cancers: The incidence of estrogen receptor beta-positive cancers is increasing globally. This is primarily attributed to the aging population and rising obesity rates. As a result, the market for estrogen receptor beta therapeutics is expected to grow significantly in the coming years.
- Growing demand for targeted therapies: There is a growing demand for targeted therapies that specifically target tumor cells with high levels of estrogen receptor beta expression. This has led to the development of several novel therapeutic agents that are currently in clinical trials. Such drugs are likely to find increased use in the future, driving growth in the Estrogen Receptor Beta market.
- Advances in biomarker research: Biomarkers play an important role in identifying patients who are likely to respond favorably to specific types of therapy targeting estrogen receptorsbeta (ERβ). This has led to advances in biomarker research, which is helping researchers develop better diagnostic tools and treatment strategies for ERβ-positive tumors. Such advances are likely to fuel growth in this market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Estrogen Receptor Beta Market Research Report
By Type
Erteberel, Estetrol, Fosfestrol, Fulvestrant, Others
By Application
Women's Health, Metabolic Disorder, Dermatology, Immunology, Others
By Companies
Acadia Pharmaceuticals Inc, AstraZeneca Plc, Atossa Genetics Inc, Chamaeleo Pharma NV, Eli Lilly and Company, Endece LLC, EndoCeutics Inc, Karo Pharma AB, Kissei Pharmaceutical Co Ltd, MEI Pharma Inc, Acadia Pharmaceuticals Inc, Oasmia Pharmaceutical AB
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
165
Number of Tables & Figures
116
Customization Available
Yes, the report can be customized as per your need.
Global Estrogen Receptor Beta Market Report Segments:
The global Estrogen Receptor Beta market is segmented on the basis of:
Types
Erteberel, Estetrol, Fosfestrol, Fulvestrant, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Women's Health, Metabolic Disorder, Dermatology, Immunology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Acadia Pharmaceuticals Inc
- AstraZeneca Plc
- Atossa Genetics Inc
- Chamaeleo Pharma NV
- Eli Lilly and Company
- Endece LLC
- EndoCeutics Inc
- Karo Pharma AB
- Kissei Pharmaceutical Co Ltd
- MEI Pharma Inc
- Acadia Pharmaceuticals Inc
- Oasmia Pharmaceutical AB
Highlights of The Estrogen Receptor Beta Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Erteberel
- Estetrol
- Fosfestrol
- Fulvestrant
- Others
- By Application:
- Women's Health
- Metabolic Disorder
- Dermatology
- Immunology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Estrogen Receptor Beta Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Estrogen receptor beta (ERbeta) is a protein that binds to estrogen and helps control the activity of other proteins. ERbeta is found in many tissues, including the brain, breast, uterus, and prostate. It plays an important role in reproductive health by regulating the production of hormones such as estrogen.
Some of the key players operating in the estrogen receptor beta market are Acadia Pharmaceuticals Inc, AstraZeneca Plc, Atossa Genetics Inc, Chamaeleo Pharma NV, Eli Lilly and Company, Endece LLC, EndoCeutics Inc, Karo Pharma AB, Kissei Pharmaceutical Co Ltd, MEI Pharma Inc, Acadia Pharmaceuticals Inc, Oasmia Pharmaceutical AB.
The estrogen receptor beta market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Estrogen Receptor Beta Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Estrogen Receptor Beta Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Estrogen Receptor Beta Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Estrogen Receptor Beta Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Estrogen Receptor Beta Market Size & Forecast, 2020-2028
4.5.1 Estrogen Receptor Beta Market Size and Y-o-Y Growth
4.5.2 Estrogen Receptor Beta Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Erteberel
5.2.2 Estetrol
5.2.3 Fosfestrol
5.2.4 Fulvestrant
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Women's Health
6.2.2 Metabolic Disorder
6.2.3 Dermatology
6.2.4 Immunology
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Estrogen Receptor Beta Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Estrogen Receptor Beta Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Erteberel
9.6.2 Estetrol
9.6.3 Fosfestrol
9.6.4 Fulvestrant
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Women's Health
9.10.2 Metabolic Disorder
9.10.3 Dermatology
9.10.4 Immunology
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Erteberel
10.6.2 Estetrol
10.6.3 Fosfestrol
10.6.4 Fulvestrant
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Women's Health
10.10.2 Metabolic Disorder
10.10.3 Dermatology
10.10.4 Immunology
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Erteberel
11.6.2 Estetrol
11.6.3 Fosfestrol
11.6.4 Fulvestrant
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Women's Health
11.10.2 Metabolic Disorder
11.10.3 Dermatology
11.10.4 Immunology
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Erteberel
12.6.2 Estetrol
12.6.3 Fosfestrol
12.6.4 Fulvestrant
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Women's Health
12.10.2 Metabolic Disorder
12.10.3 Dermatology
12.10.4 Immunology
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Erteberel
13.6.2 Estetrol
13.6.3 Fosfestrol
13.6.4 Fulvestrant
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Women's Health
13.10.2 Metabolic Disorder
13.10.3 Dermatology
13.10.4 Immunology
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Estrogen Receptor Beta Market: Competitive Dashboard
14.2 Global Estrogen Receptor Beta Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Acadia Pharmaceuticals Inc
14.3.2 AstraZeneca Plc
14.3.3 Atossa Genetics Inc
14.3.4 Chamaeleo Pharma NV
14.3.5 Eli Lilly and Company
14.3.6 Endece LLC
14.3.7 EndoCeutics Inc
14.3.8 Karo Pharma AB
14.3.9 Kissei Pharmaceutical Co Ltd
14.3.10 MEI Pharma Inc
14.3.11 Acadia Pharmaceuticals Inc
14.3.12 Oasmia Pharmaceutical AB
